Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...
It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...
One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
Generics businesses achieve pretty defendable margins, yet their valuations are at material discounts to most of the Big ...
Vertex Pharmaceuticals is an innovative powerhouse with a good stock to buy on the dip. You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have ...
Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...
Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla ... symptomatic and disease-modifying products,” Salter said. “Despite the significant anticipated growth for the AD market ...
Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...